AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00536952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
Study NCT00536952 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 5 days per week for 4 weeks
Study NCT00536952 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation Therapy
Description: 5 days per week for 4 weeks
Study NCT03925051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: mAb targeting RANKL. human monoclonal antibody targeting RANKL.
Study NCT03925051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB807
Description: human monoclonal antibody targeting RANKL.
Study NCT00701805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
Study NCT01536808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac RMI
Description: Cardiac RMI
Study NCT01536808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis telomere
Description: Analysis telomere
Study NCT01536808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress test
Description: Stress test
Study NCT01536808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: echocardiography
Study NCT00418977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Therapy (Maudsley Method)
Description: The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.
Study NCT00418977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Supportive Psychotherapy
Description: The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
Study NCT05035433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First lithotripsy and then EPBD
Description: After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
Study NCT05035433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First EPBD and then lithotripsy
Description: After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
Study NCT01956370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device for adult male circumcision
Description: The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
Study NCT01956370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical circumcision
Description: The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
Study NCT00741039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated influenza vaccine and the 23- valent pneumococcal vaccine
Description: Patients >65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
Study NCT00741039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
Description: MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
Study NCT00817115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Region-of-Interest Imaging (X-ray Fovea Imaging)
Description: Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
Study NCT02344030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: channeled blade
Description: In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
Study NCT02344030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard blade
Description: In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
Study NCT01563718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone for extended release injectable suspension
Description: VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
Study NCT01563718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone for extended release injectable suspension
Description: VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
Study NCT01144442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy with Carboplatin
Description: Carboplatin at a dose of 1000mg/m\^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
Study NCT01144442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotonic saline (perfusate)
Description: The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.
Study NCT01144442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.~If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach.
Study NCT01144442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
Study NCT01144442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
Study NCT04203628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/Rif Ultra on stool samples
Description: The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~* Standard sucrose flotation method~* Optimized sucrose flotation~* Stool processing kit (SPK)~* Simple One-step method (SOS)
Study NCT04203628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/Rif Ultra on respiratory sample
Description: The Xpert MTB/Rif Ultra will be performed on gastric aspirate or expectorated sputum
Study NCT03942354 — intervention group
Intervention type: DRUG
Intervention: Bedaquiline
Description: Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
Study NCT03942354 — intervention group
Intervention type: DRUG
Intervention: Pretomanid
Description: Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
Study NCT03942354 — intervention group
Intervention type: DRUG
Intervention: Moxifloxacin
Description: Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
Study NCT03942354 — intervention group
Intervention type: DRUG
Intervention: Linezolid
Description: Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
Study NCT03942354 — intervention group
Intervention type: DRUG
Intervention: Clofazimine
Description: Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
Study NCT03942354 — intervention group
Intervention type: DRUG
Intervention: Directly observed therapy (DOT)
Description: Standard therapy
Study NCT04645407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu tablet
Description: Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
Study NCT03076957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-516 Tablet
Description: CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
Study NCT03608579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Derived Mesenchymal Stromal Cells
Description: Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
Study NCT02171260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
Study NCT02146547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Administration in once-a-day schedule without regard to meals.
Study NCT02146547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole depot
Description: Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.
Study NCT02146547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone
Description: Administration once a day orally standardised in relation to food intake.
Study NCT02146547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone palmitate
Description: In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
Study NCT03886220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Oral; Tablet
Study NCT03886220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet
Study NCT04703439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication-taking reminders & educational materials
Description: The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
Study NCT01303822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based day-care clinic group program
Description: 11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
Study NCT04476927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiaNose
Description: DiaNose system is an electronic nose device that can smell diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases.~The DiaNose prototype system consists the following elements:~* A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.~* Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B).~* Laptop - Laptop is used to activate and save the test measurements.
Study NCT01761695 — intervention group
Intervention type: OTHER
Intervention: Diagnosed as CML
Description: All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
Study NCT01966250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture and usual care
Description: Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.~Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
Study NCT06584084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WPM-SEMG prototype
Description: Measurements will be done with the rigid matrix. The flexible electrode matrix will be used only on a lower percentage of volunteers depending on the results obtained with the rigid matrix
Study NCT03372005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floorball
Description: This intervention will have one week of testing before the first 12 weeks of floorball, followed by one week of testing before the last 27 week training period.
Study NCT01966250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
Study NCT01425398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
Study NCT01425398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
Study NCT02159794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLT Transcatheter Aortic Valve System
Description: Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
Study NCT04703439 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational materials
Description: The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
Study NCT01683981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Citrulline Malate
Description: 3 gr per day, oral, for 2 weeks
Study NCT03451318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate Nasal Spray
Description: Mometasone Furoate Nasal Spray NASONEX
Study NCT03451318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillar adenoidectomy
Description: tonsillar adenoidectomy
Study NCT01739192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Subjects will be maintained on oral bupropion or placebo during the study.
Study NCT03451318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary expander plus Twin-Block
Description: Twin-block appliance combined with maxillary expander
Study NCT01383785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intracoronary direct injection
Description: Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory.
Study NCT03910673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.
Study NCT00863031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: problem-solving therapy
Description: Three sessions of problem-solving therapy at week 1, 3 and 5.
Study NCT00863031 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Video-viewing
Description: Three sessions of viewing health educational videos.
Study NCT01943396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rheohemapheresis
Description: Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
Study NCT00712764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Study NCT00712764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01032265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based treatment with PFMT and elements of CBT
Description: 125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
Study NCT01032265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet treatment
Description: 125 women with SUI receive a pamphlet with information and a programme for PFMT.
Study NCT06370494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Healthier with Diabetes
Description: Interventions are different aspects of digital health utilizing American Diabetes Association recognized diabetes programs/applications or a combined approach. All participants were randomly assigned to their education arm and received an A1c kit, glucometer, testing strips, and surveys.
Study NCT01383785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracoronary and distal injection by aspiration device
Description: Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C.